Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | SSTR5 | P35346 | 15/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3037653 | 1.00 | HSD11B1 (0.49) | HSD11B1SSTR5KCNH2NPY5RADRA1A | |
| SCHEMBL3021457 | 0.89 | HSD11B1 (0.51) | HSD11B1SSTR5KCNH2NPY5RADRA1A | |
| SCHEMBL13045544 | 0.89 | HSD11B1 (0.51) | HSD11B1SSTR5KCNH2NPY5RADRA1A | |
| SCHEMBL2998466 | 0.89 | HSD11B1 (0.51) | HSD11B1SSTR5KCNH2NPY5RADRA1A | |
| SCHEMBL13045573 | 0.83 | HTT (0.48) | HSD11B1SSTR5KCNH2NPY5RADRA1A | |
| SCHEMBL3028745 | 0.83 | HTT (0.48) | HSD11B1SSTR5KCNH2NPY5RADRA1A | |
| SCHEMBL3036032 | 0.83 | NPY5R (0.48) | HSD11B1SSTR5KCNH2NPY5RADRA1A | |
| SCHEMBL3673029 | 0.83 | NPY5R (0.48) | HSD11B1SSTR5KCNH2NPY5RADRA1A | |
| SCHEMBL3747507 | 0.83 | HSD11B1 (0.47) | HSD11B1SSTR5KCNH2NPY5RALDH1A1 | |
| SCHEMBL2255261 | 0.83 | ALDH1A1 (0.47) | HSD11B1SSTR5ALDH1A1TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216821-A1 | Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists | BARTON NICHOLAS PAUL | 2010-08-26 | — | — | US | disclosed |
| US-20100216821-A1 | Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists | BARTON NICHOLAS PAUL | 2010-08-26 | — | — | US | disclosed |
| US-20100216821-A1 | Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists | BARTON NICHOLAS PAUL | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216821-A1 | Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists | NPY5R, NPY4R, NPY1R | HSD11B1 1359/4885SSTR5 5/4885KCNH2 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.